专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 分行业来看，统计数据显示，剔除董秘已离任公司后，A股共有35家上市体外诊断公司，其聘任总体情 况如下（部分统计口径剔除无效数据）。 从董秘的年龄分布来看，40岁-50岁董秘是市场的中坚力量，占比共计达到69%；50岁以上的董秘占比 为11%；40岁及以下董秘群体占比为20%。其中，目前仍任职的最年轻的男上市公司董秘年龄33岁，为 爱威科技的袁绘杰；最年轻的女董秘年龄为32岁，为易瑞生物的李文天。 从董秘的学历分布看，拥有本科、硕士学历的董秘占比分别为40%、60%。 从薪酬分布看，A股体外诊断公司董秘年薪平均值为77万元。经统计，处于50万以下、50万-100万、 100万-200万、200万以上各区间的人数占比分别为20%、63%、14%、3%。 其中，年薪排行前三的董秘分别为新产业的张蕾、科华生物的金红英、硕世生物的胡园园，三 ...

专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 分行业来看，统计数据显示，剔除董秘已离任公司后，A股共有35家上市体外诊断公司，其聘任总体情 况如下（部分统计口径剔除无效数据）。 从董秘的年龄分布来看，40岁-50岁董秘是市场的中坚力量，占比共计达到69%；50岁以上的董秘占比 为11%；40岁及以下董秘群体占比为20%。其中，目前仍任职的最年轻的男上市公司董秘年龄33岁，为 爱威科技的袁绘杰；最年轻的女董秘年龄为32岁，为易瑞生物的李文天。 从董秘的学历分布看，拥有本科、硕士学历的董秘占比分别为40%、60%。 从薪酬分布看，A股体外诊断公司董秘年薪平均值为77万元。经统计，处于50万以下、50万-100万、 100万-200万、200万以上各区间的人数占比分别为20%、63%、14%、3%。 其中，年薪排行前三的董秘分别为新产业的张蕾、科华生物的金红英、硕世生物的胡园园，三 ...

Group 1 - The total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Among the 35 listed companies in the in-vitro diagnostics sector, the average annual salary of secretaries is 770,000 yuan [1] - The age distribution shows that 69% of secretaries are aged between 40 and 50, while those over 50 account for 11%, and those under 40 make up 20% [1] Group 2 - The top three secretaries by salary are Zhang Lei from New Industry at 2.84 million yuan, Jin Hongying from Kehua Bio at 1.7111 million yuan, and Hu Yuanyuan from Shuoshi Bio at 1.3667 million yuan [2] - The largest salary decrease was observed for An Guozhu from Diri Medical, with a year-on-year decline of 25.82%, while the largest increase was for Wang Jianmin from Jiuqiang Bio, with a year-on-year increase of 172.86% [2]

Group 1 - The company's stock price on August 7 was 15.81 yuan, down 0.94% from the previous trading day, with a trading volume of 92,949 lots and a transaction amount of 148 million yuan [1] - The company specializes in the research, production, and sales of in vitro diagnostic products, covering areas such as autoimmune, infectious immunity, reproductive health, and diabetes monitoring, with operations in over 120 countries and regions globally [1] - Recent data indicates that the revenue from the European region accounts for less than 10% of the company's total overseas revenue, with the company stating its overseas business spans the Americas, Europe, Asia, and Africa [1] Group 2 - On the same day, the net outflow of main funds was 6.023 million yuan, with a cumulative net outflow of 8.0801 million yuan over the past five days [2]

Core Viewpoint - The stock price of Burning Stone Medical (BNR) increased by 22.95% on August 7, reaching $7.5 per share, with a total market capitalization of approximately $80.75 million [1]. Financial Performance - As of March 31, 2025, Burning Stone Medical reported total revenue of 133 million RMB, representing a year-on-year growth of 5.94% [1]. - The company recorded a net profit attributable to shareholders of -13.5 million RMB, showing a significant year-on-year improvement of 88.89% [1]. Upcoming Events - Burning Stone Medical is scheduled to disclose its mid-year report for the fiscal year 2025 on August 28, with the actual disclosure date subject to company announcements [1]. Company Background - Founded in 2014, Burning Stone Medical focuses on providing clinically valuable next-generation sequencing (NGS) for precision oncology, with a mission to "guard the light of life with science" [1]. - The company's business and research directions include: 1) detection of cancer patient populations, holding a leading market share in China; 2) collaboration with global anti-cancer pharmaceutical companies on biomarkers and companion diagnostics; 3) early detection of multiple cancer types [1]. Regulatory Milestones - In July 2018, Burning Stone Medical received the first certification for NGS testing kits for tumors from the National Medical Products Administration (NMPA) in China, marking a milestone in the field of in vitro diagnostics [2]. - The laboratory located in Guangzhou has passed the technical review by the Guangdong Provincial Clinical Testing Center and has obtained quality system certifications from CLIA and CAP in the United States [2]. - The laboratory in California has also received CLIA and CAP certifications, indicating the company's commitment to developing innovative and reliable NGS testing products [2].

Core Insights - On August 7, 2023, Burning Stone Medical (BNR) opened with a 7.7% increase, reaching $6.57 per share, with a total market capitalization of $70.7365 million [1] - As of March 31, 2025, the company's total revenue is projected to be 133 million RMB, reflecting a year-on-year growth of 5.94%, while the net profit attributable to the parent company is expected to be -13.5 million RMB, showing a significant year-on-year increase of 88.89% [1] - The company is set to disclose its mid-year report for the fiscal year 2025 on August 28, 2023 [1] Company Overview - Burning Stone Medical was established in 2014, with a mission to "protect the light of life with science," focusing on providing clinically valuable next-generation sequencing (NGS) for precision oncology [1] - The company's business and research directions primarily cover: 1) detection of cancer patient populations, holding a leading market share in China; 2) collaboration with global anti-cancer pharmaceutical companies on biomarkers and companion diagnostics; 3) early detection of multiple cancer types [1] Regulatory Milestones - In July 2018, Burning Stone Medical received the first certification for NGS testing kits for tumors from the National Medical Products Administration (NMPA) in China, marking a milestone in the field of in vitro diagnostics [2] - The laboratory located in Guangzhou, China, has passed the technical review by the Guangdong Provincial Clinical Testing Center and has obtained quality system certifications from CLIA and CAP; the laboratory in California, USA, has also received CLIA and CAP certifications [2] - The company is committed to developing innovative and reliable NGS testing products to advance the field of precision oncology [2]

Core Viewpoint - The company,透景生命, announced a plan to acquire 82% of 康录生物 for a total of 3.28 billion yuan, aiming to revitalize its growth after three consecutive years of poor performance [1][6][10]. Group 1: Acquisition Details - The acquisition will occur in three phases, starting with the purchase of 72.8630% of 康录生物, followed by additional purchases in 2026 and 2027 if certain conditions are met [6][20]. - 康录生物 specializes in the FISH technology field and has developed rapid FISH reagents and automated detection equipment, positioning itself as a leader in molecular diagnostics [7][8]. Group 2: Financial Performance - 透景生命 has experienced a decline in profits for three consecutive years, with revenue dropping from 7.16 billion yuan in 2022 to 5.43 billion yuan in 2023 [11][12]. - The company’s net profit for 2023 was reported at 89.4 million yuan, down from 124.76 million yuan in 2022 [12]. Group 3: Strategic Rationale - The acquisition is expected to create synergies in development strategy, market channels, and product technology, potentially leading to new revenue and profit growth [3][9]. - The FISH products from 康录生物 are anticipated to enhance 透景生命's product matrix and provide comprehensive solutions in tumor diagnostics [8][10]. Group 4: Risks and Commitments - The acquisition includes a performance guarantee of over 90 million yuan over three years, with specific annual profit targets set for 康录生物 [20][21]. - 康录生物's recent financial performance indicates challenges in meeting these targets, having reported revenues of 97.3 million yuan and a net profit of 16.96 million yuan in 2024 [22].

Investment Rating - The investment rating for the company is not explicitly stated in the provided content, but the report indicates a positive outlook on the company's performance and growth potential [1]. Core Viewpoints - The company reported a revenue of 579 million yuan in the first half of 2025, representing a year-over-year increase of 6.69%, and a net profit attributable to the parent company of 189 million yuan, which is a year-over-year increase of 31.41% [1][3]. - The profit growth rate outpaced revenue growth, indicating enhanced profitability with a net profit margin of 32.63%, an increase of 6.14 percentage points compared to the same period last year [3]. - The company is a leader in tumor drug companion diagnostics, with a comprehensive product system covering various technology platforms [3]. - The internationalization process is ongoing, with the company generating 137 million yuan in international sales in the first half of 2025, reflecting a year-over-year increase of 5.36% [3]. Financial Performance Summary - In the first half of 2025, the company achieved a net cash flow from operating activities of 171 million yuan, a year-over-year increase of 22.59% [1]. - The revenue from testing reagents was 483 million yuan, showing a year-over-year growth of 7.93%, while the revenue from testing services was 33 million yuan, a year-over-year increase of 0.92% [3]. - The company expects revenues of 1.255 billion yuan, 1.499 billion yuan, and 1.771 billion yuan for 2025, 2026, and 2027, respectively, with corresponding year-over-year growth rates of 13.1%, 19.5%, and 18.2% [3][4]. - The projected net profit attributable to the parent company for the same years is 355 million yuan, 439 million yuan, and 535 million yuan, with year-over-year growth rates of 39.2%, 23.6%, and 22.0% [4]. Business Segmentation - The domestic sales for the first half of 2025 reached 442 million yuan, reflecting a year-over-year increase of 7.11% despite industry pressures [3]. - The company has a dedicated international business team of over 70 people, covering more than 60 countries and regions, indicating a strong commitment to expanding its global footprint [3].

Group 1: Epidemic Overview - The recent outbreak of Chikungunya fever in southern China has led to nearly 3,000 new cases reported in just one week, primarily in Guangdong province, affecting over ten cities [1][3] - The majority of cases are concentrated in Foshan, accounting for 95% of the total cases in Guangdong, with no severe cases or deaths reported so far [3] Group 2: Government Response and Guidelines - The National Health Commission has released the "Chikungunya Fever Diagnosis and Treatment Plan (2025 Edition)," emphasizing that the disease is preventable, controllable, and treatable [3][7] - The plan incorporates traditional Chinese medicine (TCM) approaches, highlighting the role of TCM in alleviating symptoms and promoting recovery [7] Group 3: Company Initiatives - Several listed companies in the IVD (in vitro diagnostics) sector are actively developing testing products and treatment solutions for Chikungunya fever [2][4] - Shenzhen BGI Technology Co., Ltd. has introduced the T1+ gene sequencer, which can rapidly analyze samples with low viral loads, aiding in precise epidemic control [2][4] - Wanfu Biology has developed multiple testing products for Chikungunya virus detection, creating a closed-loop system for rapid screening and monitoring [4] Group 4: Traditional Chinese Medicine Applications - TCM is being utilized for symptomatic treatment of Chikungunya fever, with specific formulations recommended for managing high fever and other severe symptoms [7][8] - Companies like Guangdong Yifang Pharmaceutical and others are producing traditional Chinese medicines that have shown efficacy in treating similar viral infections [8]

（文章来源：每日经济新闻） 2024年1至12月份，新产业的营业收入构成为：体外诊断占比99.82%，其他业务占比0.18%。 新产业（SZ 300832，收盘价：55.7元）8月6日晚间发布公告称，近日，深圳市新产业生物医学工程股 份有限公司收到了广东省药品监督管理局颁发的1项《医疗器械注册证》。产品名称为"电解质分析 仪"。 ...